Author

S. Muntion

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

F. Sanchez-Guijo· 2 shared A. Alfonso-Pierola· 1 shared A. Diaz-Mazkiaran· 1 shared A. Molero· 1 shared A. Rio-Machin· 1 shared A. Vilas-Zornoza· 1 shared B. Tazon· 1 shared C. Philippe· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. Sanchez-Guijo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Transcriptional regulation of HSCs in Aging and MDS reveals DDIT3 as a Potential Driver of Dyserythropoiesis

N. Berastegui, M. Ainciburu, J. P. Romero, A. Alfonso-Pierola, C. Philippe, A. Vilas-Zornoza, P. San Martin, R. Ordonez, D. O. Alignani, S. Sarvide, L. Castro, J. M. Lamo-Espinosa, M. San-Julian, T. Jimenez, F. Lopez Cardenas, , F. Prosper

This study identifies DDIT3 as a driver of dyserythropoiesis in MDS by showing its upregulation in HSCs and its ability to disrupt erythropoiesis when overexpressed.

bioRxiv · Sep 8, 2021 · PreprintCancer Biology

CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene effect in chronic myeloid leukemia and restores normal hematopoiesis

E. Vuelta, J. L. Ordonez, V. Alonso-Perez, L. Mendez, P. Hernandez-Carabias, R. Saldana, J. Sevilla, E. Sebastian, S. Muntion, F. Sanchez-Guijo, J. M. Hernandez-Rivas, I. Garcia-Tunon, M. A. Sanchez-Martin

This study uses CRISPR/Cas9 to target and disrupt the BCR/ABL1 oncogene in CML cells, restoring normal hematopoiesis in mouse models and patient-derived xenografts.

bioRxiv · Aug 5, 2020 · PreprintCancer Biology